EZH2 has been shown to downregulate the transcription of cancer suppressor genes and control tumor cell proliferation, migration, and invasive ability by catalyzing H3K27me3.[16] In stem cell research, EZH2 leads to Runx2 inhibition and exerts a negative effect on osteogenic differentiation.[17] Hence, CGRP is assumed to reduce methylation levels of H3K27me3 and accelerate the transcription of osteogenic genes by balancing KDM6A and EZH2 in this study. This evidence concerns the gene EZH2 and cancer.